Here is the latest news from Theralase. This release updated the status of the ITA filed with Health Canada for use of the Company’s “patent pending TLC-3200 Photo Dynamic Therapy (“PDT”) Laser System and TLC-3400 Dosimetry Fibre Optic Cage (“DFOC”) technology, in conjunction with its Clinical Trial Application (“CTA”) approved lead PDC, TLD-1433, in a Phase Ib clinical trial for the treatment of Non-Muscle Invasive Bladder Cancer.”
Now Health Canada has 45 days to either approve the ITA or respond with additional questions. Everything continues to move forward with patient enrollment for the Phase 1b clinical trials coming after the ITA is approved by Health Canada.